Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellín, Colombia

Julián Esteban Londoño Hernández1, Marcia Llacuachaqui2, Gonzalo Vásquez Palacio1, Juan David Figueroa3, Jorge Madrid4, Mauricio Lema5, Robert Royer2, Song Li6, Garrett Larson6, Jeffrey N Weitzel6 and Steven A Narod2*

Abstract

Background: Approximately 5% of all breast cancers can be attributed to a mutation in the BRCA1 or BRCA2 gene. The genetic component of breast cancer in Colombia has been, for the most part, studied on cases from the Bogota region. Five different founder mutations have been identified in two studies of breast cancer patients in the Bogota region. It is important that the frequency of mutations be established among unselected cases of breast cancer of other regions of Colombia in order to estimate the genetic burden of this cancer in Colombia and to plan genetic services. The aim of this study was to establish the mutation frequencies of the BRCA genes in breast cancer patients unselected for family history or age, from Medellin, Colombia.

Methods: We enrolled 280 unselected women with breast cancer from a large public hospital in Medellin, Colombia. A detailed family history from each patient and a blood sample was obtained and processed for DNA analysis. Mutations in BRCA1 and BRCA2 were sought using a combination of techniques including a panel of recurrent Hispanic BRCA mutations which consists of fifty BRCA1 mutations and forty-six BRCA2 mutations, including the five recurrent Colombian BRCA mutations. All mutations were confirmed by direct sequencing.

Results: Genetic testing was successfully completed for 244 of the 280 cases (87%). Among the 244 cases, three deleterious mutations were identified (two in BRCA1 and one in BRCA2), representing 1.2% of the total. The average age of breast cancer in the mutation-positive cases was 34 years. The two BRCA1 mutations were known founder mutations (3450del4 in exon 11 and A1708E in exon 18). The BRCA2 mutation was in exon 11 (5844del5) and has not been previously reported in individuals of Colombian descent. Among the three mutation-positive families was a breast cancer family and two families with no history of breast or ovarian cancer.

Conclusion: The frequency of BRCA mutations in unselected breast cancer cases from the Medellin region of Colombia is low and is approximately 1.2%.

Keywords: Colombia, Breast cancer, Hereditary, BRCA1, BRCA2

Introduction

Mutations in the BRCA1 and BRCA2 genes confer high susceptibility to both breast and ovarian cancer. The lifetime risk of breast cancer in women who carry a mutation is estimated to be up to 80%, but the risk may vary according to the specific mutation, by the country of residence, and by the family history [1-5]. In Colombia, breast cancer is the most common cancer and is the second most common cause of death among women [6]. In 2008, approximately 6,655 new cases of breast cancer were diagnosed in Colombia [6]. The age-standardized incidence for breast cancer was estimated to be 31.2 cases of breast cancer per 100,000 per year [6], compared to 83.2 per 100,000 per year in Canada and 127.3 cases per 100,000 per year (whites) in the USA (SEER Registry).

Genetic testing for mutations in BRCA1 and BRCA2 has potentially important health implications as physicians could offer risk-reducing options such as prophylactic...
mastectomy and oophorectomy, tamoxifen and specialized surveillance programs for mutation carriers who have not yet developed cancer, as well as targeted cancer therapies for women with BRCA-associated cancer [7-11]. However, genetic testing is commonly available in North America, Europe, Australia and Israel, but is not generally available in South America due to its expense. Genetic testing could be made accessible to women in developing countries if common BRCA founder mutations in the two genes can be discovered or if the cost of genetic testing is reduced. Populations with a large proportion of genetically associated cancers attributable to founder mutations include the Ashkenazi Jewish [12,13], Bahamian [14], Polish [15], Mexican American [16-18], and French-Canadians [19]. The presence of founder effects within these ethnic groups has enabled rapid and low cost screening compared to the cost of complete sequencing of both BRCA genes [20].

Two previous studies have evaluated the prevalence of BRCA1 and BRCA2 mutations in breast cancer cases in the Colombian population. These studies have described five founder mutations in the Colombian population. These studies have established that low cost panel approaches to implementation of genetic services are feasible in this country. We performed mutation analysis of BRCA1 and BRCA2 on unselected patients with breast cancer from the region of Medellin, Colombia.

Material and methods
Patient population
We conducted a study on unselected breast cancer patients diagnosed at any age from February 2007 to April 2009, recruited from a single large public hospital in Medellin, Colombia (Hospital Universitario San Vicente de Paúl). In total, 280 patients were approached by the research coordinator to participate in the study during an outpatient visit to the medical oncology clinic, or during a hospital admission. All patients agreed to participate in the study. The research coordinator described the study to the patient and informed her of the implications of genetic testing. After written informed consent the patient was interviewed in person by the research coordinator for her medical and lifestyle history as well as her family history of cancer, with specific reference to a history of breast or ovarian cancer. Risk factor questionnaires, family pedigrees, and blood samples were obtained for all 280 participants. Tumor histology, tumor size, lymph node involvement and grade were abstracted from the medical records. The Bioethics Committee for Human Research of the University Research Center at Universidad de Antioquia (CBEIH-SIU) in Colombia and the Research Ethics Board at the Women's College Research Institute in Canada approved the protocol.

Laboratory methods
DNA was extracted from blood samples using Puregene DNA extraction kits at the Unidad de Genética Médica, Universidad de Antioquia in Medellin. An adequate amount of DNA was obtained for 244 of the 280 patients (87%) and a sample of this DNA was sent to the laboratory of Dr. Narod. Mutation analysis took place in the laboratory of Dr. Narod at Women's College Hospital in Toronto and in the laboratory of Dr. Weitzel at City of Hope National Medical Center in California.

Exon 11 of BRCA1 and exons 10 and 11 of BRCA2 were screened by the protein truncation test (PTT). Primer sequences used to amplify overlapping fragments for the PTT were obtained from the Breast Cancer Information Core. PTT was performed using the TNT™ rabbit reticulocyte lysate system (Promega Corporation, Madison WI), involving [35S] methionine/cysteine (New England Nuclear, Boston MA) for protein detection. We also tested for the three common mutations, BRCA1 (185delAG; 5382insC) and BRCA2 6174delIT that are most commonly seen in Ashkenazi Jews and others of eastern European ancestry. These founder mutations were assayed using a rapid multiplex method [24].

DNA samples from study subjects were also tested for a panel of recurrent mutations that is estimated to account for up to 80% of Hispanic BRCA mutations [23,25]. The panel consists of fifty BRCA1 and forty-six BRCA2 mutations, including the five recurrent Colombian BRCA mutations reported in the literature, BRCA1 (A1708E; 3450delCAAG) and BRCA2 (2034delACAA; 6076delGTTA; 6503delTT) [21,22], distributed across four multiplex PCR reactions and analyzed with Sequenom MassArray technology. BRCA1 A1708E has also been reported as a recurrent mutation in Spain and among Mexican Americans [16,26]. All deleterious mutations were confirmed by direct DNA sequencing.

Results
A total of 244 breast cancer patients were tested for BRCA1 and BRCA2 mutations using a combination of laboratory techniques. On average, 2.3 years had elapsed between the date of diagnosis and the date of interview. The mean age of the patients at diagnosis was 42 years (range 23–55) and the mean age at interview was 44 years (range 25–60). 35% of the patients were diagnosed before the age of 40 and 98% were diagnosed before the age of 50. Only 66 of the patients (27%) had a first- or second degree relative diagnosed with breast cancer or ovarian cancer at any age.
A mutation was found in 3 of 244 (1.2%) patients; two with a mutation in BRCA1 (0.8%) and one with a mutation in BRCA2 (0.4%) (Table 1). All three patients were diagnosed at age 40 or below. In this subgroup, the prevalence of mutations was 3.5%. The average age of diagnosis in the women with a BRCA mutation was 34 years, compared to 42 years for the non-carriers.

A deleterious mutation was seen in 1 of 29 patients (3.4%) with a history of breast cancer in a first-degree relative and in two of 215 (0.9%) patients with no family history of breast cancer in a first-degree relative.

A history of gastric cancer in a first- or second-degree relative was reported for 49 of 244 patients (20.1%). None were identified as a mutation carrier. Only one of the three women with a mutation had a first-degree relative affected with breast cancer. Two of 130 patients (1.5%) without a family history of any cancer were found to carry a mutation. None of the mutation carriers had a family history of cancer other than breast cancer.

Discussion

The aim of the current study was to estimate the prevalence of BRCA mutations in a series of unselected female breast cancer patients from the Medellin region in Colombia. We identified a deleterious mutation in 1.2% (3/244) of the women in the study. Among women diagnosed before age of 40, the mutation prevalence was 3.5%. Genetic testing for BRCA mutation is justified in this subgroup of women. Only two (3450del4 and A1708E) of the five reported Colombian founder mutations were identified in this study. Thus, the prevalence rate of recurrent mutations in this study is 0.8%, which is lower than the 4.2% rate (32/766) found in the unselected breast cancer cases from Bogota [22] and the 15.6% rate (15/96) found in the unselected ovarian cancer cases from Bogota [23].

Given that Colombia is a large, populous country and ethnicity varies from state to state, it is important to investigate the prevalence of mutations in other geographical areas of the country other than Bogota. So far studies have been limited to breast cancer patients and ovarian cancer patients from the Bogota region [21-23]. The prevalence rate of BRCA1 and BRCA2 mutations in this study is the lowest reported in South American studies with breast cancer populations unselected for age or family history. The prevalence rates in these South American studies range from 2.3-7.1% in Brazil (2.3%) [27], Colombia (4.2%) [22], Chile (7.1%) [28], Mexico (3.6%) (unpublished) and Venezuela (3.6%) (unpublished). The ages of diagnosis (under the age of 50) of the cases in this study is similar to that reported in these studies. This is not surprising given that in Central and South America the population is young and the majority of women with breast cancer are diagnosed under the age of 50 [29]. All three women with a BRCA mutation detected in this study were diagnosed under the age of 40, but none had a substantial family history of the disease.

The BRCA1 3450del4 founder mutation accounts for 11.5% of unselected ovarian cancers and represents 73% of BRCA mutations [23] and 1.6% of unselected breast cancers in Bogota [22]. The BRCA1 A1708E founder mutation accounts for 1.3% of unselected breast cancers [22] and 1% of unselected ovarian cancers in Bogota [23]. The latter mutation has been observed frequently in Spain [26] and in other Latin American populations [16]. The difference in mutation prevalence could be due to the fact that the patients from the Bogota and Medellin region might have different ethnicities. The high prevalence of the BRCA1 3450del4 founder mutation observed in the ovarian cancer cases suggests that there might be a regional population effect in Bogota and consequently this mutation might not have the same prevalence in other regions of Colombia, though the overall number of mutations detected was too small to draw conclusions.

The BRCA2 5844del5 mutation has never been seen before in individuals of Colombian descent, it has only been seen in seven individuals from African descent in the BIC database. The Colombian population is characterized by a high African heterogeneity and possesses an important African, Indigenous, and Spanish influence.

Our study has several limitations. We did not perform full sequencing of BRCA1 and BRCA2, nor did we screen for large rearrangements using multiplex ligation-dependent probe amplification (MLPA) with the exception of the BRCA1 ex9-12del large rearrangement. This deletion was included in the Hispanic panel employed in this study as this deletion is suggested to be a Mexican founder mutation. Nonetheless, this mutation has not been shown to be present in breast cancer patients from the Bogota region of Colombia [22] and consequently it was not observed in this study. Its absence in both Bogota and Medellin supports the likely geographic origin in Mexico. Even though full sequencing of BRCA1 and BRCA2 was not conducted,

Table 1  BRCA1 and BRCA2 mutations identified in Colombian breast cancer patients

| Patient | Gene | Exon | Mutation     | Age of diagnosis | Family history in first-second degree relatives |
|---------|------|------|--------------|------------------|-------------------------------------------------|
| 32562   | BRCA1| 11   | 3450del4     | 32               | 3 Breast Cancers (34, 32, 32)                    |
| 32531   | BRCA1| 18   | A1708E       | 34               | None                                            |
| 32259   | BRCA2| 11   | 5844del5     | 37               | None                                            |
we employed a series of laboratory techniques that included the HISPANEL panel, which is estimated to account for up to 80% of BRCA mutations in Hispanic women [23,25]. This estimate of sensitivity is based on the population in Mexico City; the sensitivity of the HISPANEL panel is currently being assessed in other Hispanic populations. In addition, more than 60% of the coding sequence of BRCA1 and 50% of the coding sequence of BRCA2 were screened by the PTT assay. Thus, there might be mutations present in the Colombian population that are not included in these assays.

Conclusion
In conclusion, we have identified a BRCA mutation in approximately 1.2% of women with breast cancer in the Medellín region of Colombia. It is our goal to document founder mutations in the various ethnic populations of Central and South America to ultimately create a cost-efficient genetic tool that could identify women at high-risk in these countries for the purpose of cancer control.

Competing interest
The authors declare that they have no competing interests.

Authors’ contributions
JELH interviewed the participants, collected information, and helped draft the manuscript. ML2 analyzed the research data and wrote the manuscript. GVP participated in the design of the study, coordination, and in the supervision of the accrual of study participants. JDF, JM, and ML5 participated in the supervision of the accrual of study participants. RR and SL conducted part of the mutation analysis using the Hispanic mutation panel in California. SN conducted part of the mutation analysis in Toronto. GL and JNW conducted MRI surveillance for hereditary breast-cancer risk. JELH interviewed the participants, collected information, and helped draft the manuscript. All authors read and approved the final manuscript.

Authors’ information
Co-first author: Marcia Llacuachaqui

Acknowledgments
We thank Josef Herzog for his assistance in the Weitzel laboratory. The project was supported in part by American Cancer Society grant #RSGT-00-263-01 for the Hispanic BRCA mutation panel assays, and by the City of Hope Clinical Cancer Genetics Community Research Network, supported by Award Number R01CA153828 (PI. J. Weitzel) from the National Cancer Institute and the Office of the Director, National Institutes of Health, and the National Cancer Institute.

Author details
1Unidad de Genética Médica, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. 2Women’s College Research Institute, 790 Bay Street, 7th Floor, Toronto, Ontario M5G 1N8, Canada. 3Hospital Pablo Tobón Uribe, Medellín, Colombia. 4Clínica Las Américas, Medellín, Colombia. 5Clínica de Oncología Astorga, Clínica SOM, Medellín, Colombia. 6City of Hope National Medical Center, Duarte, CA, USA.

Received: 3 October 2013 Accepted: 31 December 2013 Published: 17 April 2014

References
1. Antoniou A, Pharaoh PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasi J, Radice P, Manoukian S, Eccles D, Mistry N, Tashjian A, Anton-Culver H, Beppu M, Loman N, Schmutzler RK, Kjaer SK, Lerman C, Struewing JP, Warner E, Rosen B, Lerman C, de la Iglesia A, Foulkes WD, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya RD, Krainer M, Haber DA, Stuweving JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996, 2:1179–1183.
2. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
3. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
4. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
5. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
6. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
7. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
8. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
9. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
10. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
11. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
12. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235–244.
20. Narod SA: Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. Salud Publica Mex 2009, 51:191–196.
21. Torres D, Rashid MU, Gil F, Umaña A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamman U: High proportion of BRCA1/2 founder mutations in hispanic breast/ovarian cancer families from colombia. Breast Cancer Res Treat 2007, 103:225–232.
22. Torres D, Umaña A, Robledo JF, Caicedo JJ, Quintero E, Orozco A, Torregrosa L, Tawil M, Hamman U, Briceno I: Estudio de factores genéticos para cáncer de mama en colombia. Univ Med Bogotá (Colombia) 2009, 50:297–301.
23. Rodríguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN, Narod SA: BRCA1 and BRCA2 mutations among ovarian cancer patients from colombia. Gynecol Oncol 2012, 124:236–243.
24. Kuperstein G, Jack E, Narod SA: A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene. Genet Test 2006, 10:1–7.
25. Weitzel J: Ancestry-informed strategies for genetic cancer risk assessment, screening and prevention: adapting the lessons to underserved latinas. San Antonio, TX: 33rd Annual San Antonio Breast Cancer Symposium; 2010.
26. de la Hoya M, Ostorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodriguez R, Diaz-Rubio E, Benitez J, Devilee P, Caldes T: Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 2002, 97:466–471.
27. Gomes MC, Costa MM, Borajevic R, Monteiro AN, Vieira R, Kofman S, Li S, Royer R, Zhang S, Narod SA: Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2007, 103:349–353.
28. Gonzalez-Hormazabal P, Gutierrez-Enriquez S, Gaete D, Reyes JM, Peralta O, Waugh E, Gomez F, Margarit S, Bravo T, Blanco R, Diiez O, Jara L: Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer chilean families. Breast Cancer Res Treat 2011, 126:705–716.
29. Bosetti C, Rodriguez T, Chatenoud L, Bertuccio P, Levi F, Negri E, La Vecchia C: Trends in cancer mortality in Mexico, 1981–2007. Eur J Cancer Prev 2011, 20:355–363.

doi:10.1186/1897-4287-12-11
Cite this article as: Hernández et al: Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellin, Colombia. Hereditary Cancer in Clinical Practice 2014 12:11.